Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies. These ready-made antibodies are suitable for developing selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for dupilumab, evolocumab, ipilimumab, and secukinumab, and their biosimilars.

Dupilumab limits inflammatory immune responses by targeting IL-4Ra and is approved for treatment of severe atopic eczema. Bio-Rad’s six new anti-dupilumab antibodies can be used to develop PK bridging ELISAs to measure free and total drug, or as a surrogate positive control or reference standard in ADA assaysThe range includes two fully human IgG1 clones and four TrailBlazer™ Antibodies with a SpyTag incorporated into their heavy chain, enabling site-directed conjugation or fast switching to a bivalent Fab or a full-length Ig-like format within an hour.

Bio-Rad has also expanded its anti-ipilimumab and anti-secukinumab portfolio to become the first provider of antibodies specific to the drug-target complex, allowing the detection of bound drug. HRP-labeled TrailBlazer antibodies are also now available for evolocumab.

“Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility for the development of highly selective and highly sensitive bioanalytical assays,” said Dr. John Cardone, Marketing Manager, Custom Antibodies, Life Science Group, Bio-Rad. “Our drug-target complex binders are unique to Bio-Rad, enabling researchers to detect drugs in the target-bound state, and all our anti-idiotypic antibodies are provided with in-depth data packages for reproducible results.”

These new anti-idiotypic antibodies are approved for in vitro research, for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.

To learn more about Bio-Rad’s anti-idiotypic antibodies, please visit

BIO-RAD and TRAILBLAZER are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. Products containing SpyTag1, SpyTag3, SpyCatcher1 or SpyCatcher3 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, and 10,527,609. Products containing SpyTag2 or SpyCatcher2 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, 10,527,609, and 11,059,867

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,200 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements are based on assumptions and expectations of future events that are subject to risks and uncertainties, which could cause actual results to vary materially from the plans, goals, and expectations expressed in or indicated by the forward-looking statements. These risks and uncertainties include the impact of the COVID-19 pandemic, supply chain risks, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, reductions in government funding and the capital spending programs of our customers, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:

Bio-Rad Laboratories, Inc.

Katrina Academia, Inbound Marketing Manager

[email protected]

Zyme CommunicationsEsmé Walters

[email protected]

< | >